Diagnostic Criteria of Autoimmune Hepatitis
Overview
Affiliations
Autoimmune hepatitis (AIH) is a chronic immune-mediated liver disorder characterised by female preponderance, elevated transaminase and immunoglobulin G levels, seropositivity for autoantibodies and interface hepatitis. Presentation is highly variable, therefore AIH should be considered during the diagnostic workup of any increase in liver enzyme levels. A set of inclusion and exclusion criteria for the diagnosis of AIH have been established by the International Autoimmune Hepatitis Group (IAIHG). There are two main types of AIH: type 1, positive for anti-nuclear (ANA) and/or anti-smooth muscle antibodies (SMAs) and type 2, defined by the presence of anti-liver kidney microsomal antibody type 1 (LKM-1) and/or anti-liver cytosol type 1 (LC-1) autoantibodies. The central role of autoantibodies in the diagnosis of AIH has led the IAIHG to produce a consensus statement detailing appropriate and effective methods for their detection. Autoantibodies should be tested by indirect immunofluorescence at an initial dilution of 1/40 in adults and 1/10 in children on a freshly prepared rodent substrate that includes kidney, liver and stomach sections to allow for the simultaneous detection of all reactivities relevant to AIH. Anti-LKM-1 is often confused with anti-mitochondrial antibody (AMA) if rodent kidney is used as the sole immunofluorescence substrate. The identification of the molecular targets of anti-LKM-1 and AMA has led to the establishment of immuno-assays based on the use of the recombinant or purified autoantigens. Perinuclear anti-nuclear neutrophil antibody (p-ANNA) is an additional marker of AIH-1; anti soluble liver antigen (SLA) antibodies are specific for autoimmune liver disease, can be present in AIH-1 and AIH-2 and are associated with a more severe clinical course. Anti-SLA are detectable by ELISA or radio-immuno-assays, but not by immunofluorescence. AIH is exquisitely responsive to immunosuppressive treatment, which should be instituted promptly to prevent rapid deterioration and promote remission and long-term survival.
Chi G, Pei J, Li X PLoS One. 2024; 19(6):e0305220.
PMID: 38848323 PMC: 11161122. DOI: 10.1371/journal.pone.0305220.
Yilmaz K, Haeberle S, Kim Y, Fritzler M, Weng S, Goeppert B Front Immunol. 2023; 14:1253649.
PMID: 37818371 PMC: 10561387. DOI: 10.3389/fimmu.2023.1253649.
Autoantibody profile in sarcoidosis, analysis from the GRADS sarcoidosis cohort.
Khassawneh B, Zhu C, Barkes B, Vestal B, Shrock S, Gillespie M PLoS One. 2022; 17(10):e0274381.
PMID: 36264970 PMC: 9584415. DOI: 10.1371/journal.pone.0274381.
Kolev M, Horn M, Semmo N, Nagler M J Transl Autoimmun. 2022; 5:100151.
PMID: 35309737 PMC: 8927991. DOI: 10.1016/j.jtauto.2022.100151.
Andrade L, Damoiseaux J, Vergani D, Fritzler M J Transl Autoimmun. 2022; 5:100145.
PMID: 35128372 PMC: 8804266. DOI: 10.1016/j.jtauto.2022.100145.